Trial

Registry

Number

Phase

Stage

Treatment

Primary

Endpoint

Trial Status

Checkmate 816

NCT02998528

III

IB-IIIA

Chemotherapy + Nivolumab

vs. Chemotherapy

pCR and EFS improvement

with nivolumab

Completed

KEYNOTE-617

NCT03425643

III

IIB-IIIA

Chemotherapy + pembrolizumab

EFS and OS

Active, not recruiting

IMpower 030

NCT03456063

III

II-IIIB

Chemotherapy + atezolizumab

EFS

Active, not recriting

NEOSTAR

NCT03158129

II

I–IIIA

Nivolumab or

Nivolumab + Ipilimumab

MPR

Active,

recriting

NCT04326153

II

IIIA

Sintilimab + chemotherapy

vs. chemotherapy

DFS

Active,

recruiting

NCT04989283

II

IIB-IIIA

(superior sulcus tumors)

Atezolizumab + chemoradiation vs. chemoradiation

pCR

Active

recruiting